Prescription drugs

Ozempic Hype Forces Employer Calls on Obesity Coverage

Employers are facing a big dilemma: How do they pay for the new highly effective and popular obesity medications without breaking the bank?

Read More

How Patents Help Keep Obesity Drug Prices Sky-High

A recent JAMA study sheds light on how the manufacturers of a class of popular weight-loss drugs have avoided competition from more affordable generics.

Read More

What to Expect When Medicare and Pharma Finally Negotiate Drug Prices

We explain how Medicare’s historic price negotiations with drugmakers will work, and the impact they could have.

Read More

Can Medicare Afford to Foot the Bill for New Alzheimer’s Drugs?

Recent analyses in JAMA and by the Kaiser Family Foundation raise questions about whether Medicare and its beneficiaries can afford a new wave of Alzheimer’s treatments.

Read More

Should Remote Opioid Addiction Treatment Stay in the Mix?

Two recent studies show the impact of an ongoing, COVID-era rule that let doctors treat opioid addiction entirely remotely.

Read More

Medicare Director Meena Seshamani on CMS’ New Drug Pricing Powers

Medicare director Meena Seshamani discusses her team’s sprint to put historic drug price reforms into action.

Read More

Medicare Releases Details of Major Drug Price Reform

Medicare’s historic plan to slow prescription drug spending is taking shape.

Read More

The End of Humira’s $200 Billion Drug Monopoly

What will happen when the best selling drug ever finally faces direct competition?

Read More

‘Three Health Policy Stories to Watch in 2023’ Transcript

In 2023 states will pursue new abortion laws, restart Medicaid eligibility checks and Medicare begins to flex its new power to negotiate drug prices.

Read More

Local Officials Grapple With How to Spend Billions in Opioid Settlement Dollars

More than $50 billion in opioid settlement dollars from drugmakers, distributors and pharmacies are starting to flow to state and local governments.

Read More